Hallux Garners $7,100,000 Series A Funding Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    Undisclosed Orange, CA 92856 USA
  • Company Description
    Hallux is developing an investigational micro-insert for subungual delivery and treatment of distal lateral subungual onychomycosis. The dosage form is biodegradable and delivers high concentrations of terbinafine hydrochloride, the highly effective leading anti-fungal, directly and selectively to the site of infection.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series A
  • Proceeds Purposes
    The new capital will be deployed to advance Hallux’s proprietary terbinafine micro-insert dosage form into phase 2A clinical trials, with the goal of demonstrating safety, efficacy, and tolerability in patients with distal lateral subungual onychomycosis.
  • M&A Terms
  • Venture Investor
    Deerfield Capital
  • Venture Investor

Trending on Xconomy